Literature DB >> 21491084

Mode of action of trifluorothymidine (TFT) against DNA replication and repair enzymes.

Norihiko Suzuki1, Tomohiro Emura, Masakazu Fukushima.   

Abstract

Trifluorothymidine (TFT) is well known to be converted to TFT-monophosphate by thymidine kinase and to inhibit thymidylate synthase. In addition, TFT-triphosphate (TFT-TP) is also incorporated into DNA, resulting in cytocidal effects. However, the precise mechanism of TFT-induced DNA damage is still unclear. Therefore, we investigated the modes of action of TFT against DNA replication and repair enzymes, as compared with those of 5FU and FdUrd. When HeLa cells were treated with TFT at a concentration of 1 µM (IC50 value), the concentration of TFT in the DNA was calculated as 62.2±0.9 pmol/1x106 cells for 4 h. On the other hand, following treatment of the cells with FdUrd (0.5 µM) and 5FU (10 µM) at their IC50 doses, the drug concentrations in the DNA were 7.53, and 0.17 pmol/1 x 10⁶ cells for 4 h, respectively. These results show the markedly greater degree of incorporation of TFT into the DNA of the HeLa cells compared with that of 5FU (approximately more than 300-fold for 4 h) or FdUrd (approximately more than 8-fold for 4 h). The primer extension assay demonstrated that TFT-TP was also incorporated into the T-sites of the growing DNA strand, however, it competed only weakly with thymidine triphosphate. The DNA glycosylase assay was performed using commercially available DNA glycosylase and fractionated HeLa cell extracts obtained by gel filtration. There was no detectable excision of the TFT pairing to adenine by uracil DNA glycosylase (UDG), thymine DNA glycosylase (TDG), methyl-CpG binding domain 4 (MBD4) or the fractionated HeLa cell extracts, however, TDG and MBD4 were able to excise the TFT pairing to guanine. Additional data indicate that small-interfering RNA-mediated knockdown of TDG or MBD4 significantly increased the resistance to the cytotoxic effects of FdUrd, but not to that of TFT. These studies show the greater degree of incorporation of TFT into the DNA than that of 5FU or FdUrd, and that such a high degree of incorporation of TFT residues into the DNA might be related to exhibit potent cytotoxic activity to be refractory to cleavage by these DNA glycosylases; thus, the DNA-directed cytotoxic effect of the compound is quite different from that of 5FU.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21491084     DOI: 10.3892/ijo.2011.1003

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  22 in total

Review 1.  TAS-102, a novel antitumor agent: a review of the mechanism of action.

Authors:  Heinz-Josef Lenz; Sebastian Stintzing; Fotios Loupakis
Journal:  Cancer Treat Rev       Date:  2015-06-06       Impact factor: 12.111

2.  Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks.

Authors:  Norihiko Suzuki; Fumio Nakagawa; Mamoru Nukatsuka; Masakazu Fukushima
Journal:  Exp Ther Med       Date:  2011-03-21       Impact factor: 2.447

Review 3.  Human pyrimidine nucleotide biosynthesis as a target for antiviral chemotherapy.

Authors:  Ayse Okesli; Chaitan Khosla; Michael C Bassik
Journal:  Curr Opin Biotechnol       Date:  2017-04-27       Impact factor: 9.740

Review 4.  Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer.

Authors:  Celeste B Burness; Sean T Duggan
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

Review 5.  TAS-102: a novel antimetabolite for the 21st century.

Authors:  Nataliya Uboha; Howard S Hochster
Journal:  Future Oncol       Date:  2015-11-30       Impact factor: 3.404

6.  Synergistic anticancer activity of a novel oral chemotherapeutic agent containing trifluridine and tipiracil in combination with anti-PD-1 blockade in microsatellite stable-type murine colorectal cancer cells.

Authors:  Norihiko Suzuki; Hiroshi Tsukihara; Fumio Nakagawa; Takashi Kobunai; Teiji Takechi
Journal:  Am J Cancer Res       Date:  2017-10-01       Impact factor: 6.166

Review 7.  Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.

Authors:  Peter M Wilson; Peter V Danenberg; Patrick G Johnston; Heinz-Josef Lenz; Robert D Ladner
Journal:  Nat Rev Clin Oncol       Date:  2014-04-15       Impact factor: 66.675

8.  Identification of genotoxic compounds using isogenic DNA repair deficient DT40 cell lines on a quantitative high throughput screening platform.

Authors:  Kana Nishihara; Ruili Huang; Jinghua Zhao; Sampada A Shahane; Kristine L Witt; Stephanie L Smith-Roe; Raymond R Tice; Shunichi Takeda; Menghang Xia
Journal:  Mutagenesis       Date:  2015-08-04       Impact factor: 3.000

9.  Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.

Authors:  T Doi; A Ohtsu; T Yoshino; N Boku; Y Onozawa; A Fukutomi; S Hironaka; W Koizumi; T Sasaki
Journal:  Br J Cancer       Date:  2012-06-26       Impact factor: 7.640

10.  Structural Insights into the Mechanism of Base Excision by MBD4.

Authors:  Lakshmi S Pidugu; Hilary Bright; Wen-Jen Lin; Chandrima Majumdar; Robert P Van Ostrand; Sheila S David; Edwin Pozharski; Alexander C Drohat
Journal:  J Mol Biol       Date:  2021-06-06       Impact factor: 6.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.